We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PIE II: Pharmacological Intervention in the Elderly II

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00123955
First Posted: July 26, 2005
Last Update Posted: March 13, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Dalane W. Kitzman, Wake Forest School of Medicine
  Purpose
The purpose of this study is to examine whether spironolactone will improve exercise tolerance and quality of life in elderly patients with heart failure preserved ejection fraction (HFPEF).

Condition Intervention Phase
Diastolic Heart Failure Heart Failure, Congestive Drug: Spironolactone Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Exercise Intolerance in Elderly Diastolic Heart Failure

Resource links provided by NLM:


Further study details as provided by Dalane W. Kitzman, Wake Forest School of Medicine:

Primary Outcome Measures:
  • Exercise Intolerance [ Time Frame: Baseline, 4 and 9 months ]
    Peak exercise VO2

  • Quality of Life [ Time Frame: Baseline, 4 and 9 months ]

Secondary Outcome Measures:
  • Concentric Left Ventricular Remodeling [ Time Frame: Baseline, 4 and 9 months ]
  • Left Ventricular Diastolic Stiffness [ Time Frame: Baseline, 4 and 9 months ]

Enrollment: 80
Study Start Date: April 2005
Study Completion Date: December 2012
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Spironolactone
Drug: Spironolactone
25mg tablet daily for 9 months
Other Name: Aldactone
Placebo Comparator: 2
Placebo
Drug: Placebo
Placebo tablet daily for 9 months

Detailed Description:
Exercise intolerance due to HFPEF is a major cause of disability among older Americans. Several lines of evidence suggest that aldosterone antagonism may improve exercise tolerance in HFPEF. Therefore, the primary aim of this study is to test the hypothesis that spironolactone will improve exercise tolerance and quality of life in elderly patients with isolated HFPEF. A total of 72 participants aged 60 or older will be randomized to receive either spironolactone 25mg daily or a placebo.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ambulatory
  • Medically stable
  • Ages 60 or older
  • Diagnosis of diastolic heart failure

Exclusion Criteria:

  • Valvular heart disease
  • Significant change in cardiac medication within the past 4 weeks
  • Uncontrolled hypertension
  • Recent or debilitating stroke
  • Cancer or other noncardiovascular conditions with life expectancy less than 2 years
  • Anemia
  • Elevated serum potassium
  • Renal insufficiency
  • Psychiatric disease (uncontrolled major psychoses, depression, dementia, or personality disorder)
  • Allergy to spironolactone; currently taking spironolactone or any aldosterone antagonist
  • Plans to leave area within 1 year
  • Refuses informed consent
  • Failure to pass screening tests: pulmonary function, echocardiogram, or exercise
  • Contra-indications to magnetic resonance imaging [MRI] (indwelling metal-containing prosthesis; pacemaker or defibrillator; history of welding occupation; uncontrollable claustrophobia)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00123955


Locations
United States, North Carolina
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157
Sponsors and Collaborators
Wake Forest University Health Sciences
National Institute on Aging (NIA)
Investigators
Principal Investigator: Dalane W. Kitzman, MD Professor of Internal Medicine, Cardiology, Director of Echocardiography, Wake Forest University Health Sciences
  More Information

Publications:

Responsible Party: Dalane W. Kitzman, Professor Internal Medicine Cardiology/Gerontology, Wake Forest School of Medicine
ClinicalTrials.gov Identifier: NCT00123955     History of Changes
Other Study ID Numbers: AG0030
R01AG018915 ( U.S. NIH Grant/Contract )
2R01AG018915-05 ( U.S. NIH Grant/Contract )
First Submitted: July 22, 2005
First Posted: July 26, 2005
Results First Submitted: February 6, 2015
Results First Posted: February 23, 2015
Last Update Posted: March 13, 2015
Last Verified: February 2015

Additional relevant MeSH terms:
Heart Failure
Heart Failure, Diastolic
Heart Diseases
Cardiovascular Diseases
Spironolactone
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Diuretics
Natriuretic Agents